A Phase 1 interventional study of vorinostat and decitabine in Leukemia, Myelocytic, Acute Myelodysplastic Syndromes and Myelodysplastic Syndromes, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-09-21.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing vorinostat in Leukemia — none open to participants now, 1 under way, 1 of them phase 3. Vorinostat · Leukemia.
Among the 10 studies testing vorinostat in Leukemia, this one is the only one that started in 2007, is one of 4 in phase 1, and was the 2nd registered.
2,382 studies on the registry are indexed under Leukemia; 254 are open to participants now.
Browse Leukemia studies →None of the 10 studies testing vorinostat in Leukemia is open now. The open studies under Leukemia, anywhere →
Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →
Of the 208 Leukemia studies recruiting now, 112 (54%) set no upper age limit and 74 (36%) stop at 75 or younger; 86 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6 · Phase 3 1
First in 2000; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 71 is above the median of 40 across 1,770 interventional studies indexed under Leukemia.
Median enrollment 37 across the 9 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 10 have an industry lead sponsor. The 8 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
10 studies in Leukemia by Merck & Co., Inc: none open now, 1 under way, none of them phase 3. Of 9 finished, 3 (33%) have results posted.
Among the 10 studies in Leukemia by Merck & Co., Inc, this one is the only one that started in 2007, is one of 4 in phase 1, and was the 5th registered.
Merck & Co., Inc’s Leukemia studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing vorinostat in Leukemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 10 in Leukemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to evaluate the safety and tolerability of vorinostat in combination with decitabine as well as the in vivo molecular and biological effects of vorinostat in patients with refractory or relapsed Acute Myelogenous Leukemia (AML) and intermediate or high risk as defined by International Prognostic Scoring System (IPSS) Myelodysplastic Syndrome (MDS). Participants with Acute Myelogenous Leukemia or Myelodysplastic Syndrome are eligible.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient is at least 18 years old with /relapsed AML
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vorinostat 400 mg capsules once daily given 7, 10 or 14 days in 28 day cycles. Up to 24 months of treatment. Decitabine IV 20 mg/m\^2 daily for 5 days in each 28 day cycle. Up to 24 months of treatment.
Drug: vorinostat · Drug: decitabine
Vorinostat 400 mg capsules once daily given 7 days, 14 days with 8 day break after first 7 days or 14 days without break, out of 28 day cycles. Decitabine IV 20 mg/m\^2 daily for 5 days in each 28 day cycle. Up to 24 months of treatment.
Drug: vorinostat · Drug: decitabine
Also known as: MK-0683, SAHA
Also known as: Dacogen
Number of Participants Experiencing Dose Limiting Toxicity (DLT) Events
Participants who received at least one dose of vorinostat in combination with decitabine intravenous (IV) at a dose of 20 mg/m\^2 daily for 5 days along with oral vorinostat 400 mg once daily for 7 to 14 days in a 28-day cycle concurrently or sequentially, were evaluated to determine the maximum tolerable dose (MTD) determined by the number of participants experiencing dose limiting toxicity (DLT) events defined as any Grade 3 or 4 non-hematological toxicity (reported adverse event) and/or myelosuppression lasting \>42 days.
Time frame: Day 1 to 28 of Cycle 1
Objective Response Rate in Participants Treated With Vorinostat + Decitabine With Refractory or Relapse Acute Myelogenous Leukemia (AML)
Objective Response Rate was measured in participants with refractory or relapse AML (acute myelogenous leukemia) in combination with Decitabine who were treated with vorinostat and decitabine on either a concurrent or sequential regimen. The Objective response was defined as any confirmed complete remission or any confirmed partial remission for AML participants and complete remission, confirmed partial remission or confirmed hematologic improvement for Myelodysplastic Syndrome (MDS) participants.
Time frame: Approximately 6 months
Objective Response Rate in Participants Treated With Vorinostat + Decitabine With Intermediate-high Risk Myelodysplastic Syndrome (MDS) or Untreated Acute Myelogenous Leukemia (AML)
Objective Response Rate was measured in participants with intermediate-high risk MDS or untreated AML who were treated with vorinostat and decitabine either on a concurrent or sequential regimen. The Objective response was defined as any confirmed complete remission or any confirmed partial remission for AML participants and complete remission, confirmed partial remission or confirmed hematologic improvement for MDS participants.
Time frame: Approximately 6 months
| Milestone | Concurrent, Vorinostat 400mg qd x 7d/4wk + Decitabine | Concurrent, Vorinostat 400mg qd x 7d/2wk + Decitabine | Concurrent, Vorinostat 400mg qd x 14d/4wk + Decitabine (MTD) | Sequential, Vorinostat 400mg qd x 7d/4wk + Decitabine | Sequential, Vorinostat 400mg qd x 10d/4wk + Decitabine | Sequential, Vorinostat 400mg qd x 14d/4wk + Decitabine (MTD) |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 28 | 3 | 4 | 30 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 3 | 28 | 3 | 4 | 30 |
| Withdrew: Adverse event | 0 | 0 | 5 | 0 | 0 | 10 |
| Withdrew: Deviation from protocol | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 | 0 | 0 | 4 |
| Withdrew: Physician decision | 0 | 0 | 2 | 0 | 0 | 1 |
| Withdrew: Progressive disease | 3 | 1 | 12 | 3 | 3 | 12 |
| Withdrew: Withdrew consent | 0 | 2 | 6 | 0 | 1 | 3 |
Participants who received at least one dose of vorinostat in combination with decitabine intravenous (IV) at a dose of 20 mg/m\^2 daily for 5 days along with oral vorinostat 400 mg once daily for 7 to 14 days in a 28-day cycle concurrently or sequentially, were evaluated to determine the maximum tolerable dose (MTD) determined by the number of participants experiencing dose limiting toxicity (DLT) events defined as any Grade 3 or 4 non-hematological toxicity (reported adverse event) and/or myelosuppression lasting \>42 days.
| participants | Concurrent, Vorinostat 400mg qd x 7d/4wk + Decitabine | Concurrent, Vorinostat 400mg qd x 7d/2wk + Decitabine | Concurrent, Vorinostat 400mg qd x 14d/4wk + Decitabine (MTD) | Sequential, Vorinostat 400mg qd x 7d/4wk + Decitabine | Sequential, Vorinostat 400mg qd x 10d/4wk + Decitabine | Sequential, Vorinostat 400mg qd x 14d/4wk + Decitabine (MTD) |
|---|---|---|---|---|---|---|
| Number of Participants Experiencing Dose Limiting Toxicity (DLT) Events | 0 | 0 | 0 | 0 | 0 | 1 |
Objective Response Rate was measured in participants with refractory or relapse AML (acute myelogenous leukemia) in combination with Decitabine who were treated with vorinostat and decitabine on either a concurrent or sequential regimen. The Objective response was defined as any confirmed complete remission or any confirmed partial remission for AML participants and complete remission, confirmed partial remission or confirmed hematologic improvement for Myelodysplastic Syndrome (MDS) participants.
| percentage of participants | Refractory or Relapsed AML, Concurrent | Refractory or Relapsed AML, Sequential |
|---|---|---|
| Objective Response Rate in Participants Treated With Vorinostat + Decitabine With Refractory or Relapse Acute Myelogenous Leukemia (AML) | 7.1 ± 0 | 0.0 ± NA |
Objective Response Rate was measured in participants with intermediate-high risk MDS or untreated AML who were treated with vorinostat and decitabine either on a concurrent or sequential regimen. The Objective response was defined as any confirmed complete remission or any confirmed partial remission for AML participants and complete remission, confirmed partial remission or confirmed hematologic improvement for MDS participants.
| percentage of participants | Untreated AML or Intermediate, Concurrent | Untreated AML or Intermediate, Sequential |
|---|---|---|
| Objective Response Rate in Participants Treated With Vorinostat + Decitabine With Intermediate-high Risk Myelodysplastic Syndrome (MDS) or Untreated Acute Myelogenous Leukemia (AML) | 35.0 ± 170.3 | 13.6 ± 119.2 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Concurrent, Vorinostat 400 mg qd x 7d/4wk + Decitabine | — | 3/3 (100%) | 3/3 (100%) |
| Concurrent, Vorinostat 400 mg qd x 7d/2wk + Decitabine | — | 1/3 (33.3%) | 3/3 (100%) |
| Concurrent, Vorinostat 400 mg qd x 14d/4wk + Decitabine (MTD) | — | 21/28 (75%) | 27/28 (96.4%) |
| Sequential, Vorinostat 400 mg qd x 7d/4wk + Decitabine | — | 2/3 (66.7%) | 3/3 (100%) |
| Sequential, Vorinostat 400 mg qd x 10d/4wk + Decitabine | — | 4/4 (100%) | 4/4 (100%) |
| Sequential,Vorinostat 400 mg qd x 14d/4wk + Decitabine (MTD) | — | 25/31 (80.6%) | 29/31 (93.5%) |
| Event | Concurrent, Vorinostat 400 mg qd x 7d/4wk + Decitabine | Concurrent, Vorinostat 400 mg qd x 7d/2wk + Decitabine | Concurrent, Vorinostat 400 mg qd x 14d/4wk + Decitabine (MTD) | Sequential, Vorinostat 400 mg qd x 7d/4wk + Decitabine | Sequential, Vorinostat 400 mg qd x 10d/4wk + Decitabine | Sequential,Vorinostat 400 mg qd x 14d/4wk + Decitabine (MTD) |
|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 3/3 | 0/3 | 6/28 | 0/3 | 2/4 | 1/31 |
| Atrial fibrillationCardiac disorders | 2/3 | 0/3 | 0/28 | 0/3 | 0/4 | 1/31 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/3 | 1/3 | 12/28 | 1/3 | 1/4 | 7/31 |
| Pericardial effusionCardiac disorders | 1/3 | 0/3 | 0/28 | 0/3 | 1/4 | 0/31 |
| Sinus bradycardiaCardiac disorders | 1/3 | 0/3 | 0/28 | 0/3 | 0/4 | 0/31 |
| CaecitisGastrointestinal disorders | 0/3 | 0/3 | 0/28 | 1/3 | 0/4 | 0/31 |
| NauseaGastrointestinal disorders | 1/3 | 0/3 | 1/28 | 0/3 | 0/4 | 1/31 |
| PancreatitisGastrointestinal disorders | 1/3 | 0/3 | 0/28 | 0/3 | 0/4 | 0/31 |
| DeathGeneral disorders | 1/3 | 0/3 | 0/28 | 0/3 | 0/4 | 0/31 |
| Multi-organ failureGeneral disorders | 0/3 | 1/3 | 0/28 | 0/3 | 0/4 | 0/31 |
| Event | Concurrent, Vorinostat 400 mg qd x 7d/4wk + Decitabine | Concurrent, Vorinostat 400 mg qd x 7d/2wk + Decitabine | Concurrent, Vorinostat 400 mg qd x 14d/4wk + Decitabine (MTD) | Sequential, Vorinostat 400 mg qd x 7d/4wk + Decitabine | Sequential, Vorinostat 400 mg qd x 10d/4wk + Decitabine | Sequential,Vorinostat 400 mg qd x 14d/4wk + Decitabine (MTD) |
|---|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 0/3 | 3/3 | 9/28 | 0/3 | 0/4 | 6/31 |
| Sinus tachycardiaCardiac disorders | 3/3 | 0/3 | 1/28 | 1/3 | 1/4 | 0/31 |
| DiarrhoeaGastrointestinal disorders | 2/3 | 3/3 | 16/28 | 1/3 | 3/4 | 15/31 |
| NauseaGastrointestinal disorders | 2/3 | 1/3 | 17/28 | 3/3 | 3/4 | 20/31 |
| FatigueGeneral disorders | 3/3 | 1/3 | 11/28 | 2/3 | 3/4 | 19/31 |
| HypocalcaemiaMetabolism and nutrition disorders | 0/3 | 0/3 | 2/28 | 3/3 | 0/4 | 2/31 |
| HypophosphataemiaMetabolism and nutrition disorders | 2/3 | 1/3 | 4/28 | 3/3 | 2/4 | 1/31 |
| HeadacheNervous system disorders | 3/3 | 2/3 | 7/28 | 1/3 | 0/4 | 5/31 |
| ConstipationGastrointestinal disorders | 2/3 | 0/3 | 16/28 | 1/3 | 3/4 | 11/31 |
| DyspepsiaGastrointestinal disorders | 1/3 | 0/3 | 1/28 | 0/3 | 3/4 | 1/31 |
| Age, Continuous(years) | Vorinostat + Decitabine, Concurrent | Vorinostat + Decitabine, Sequential | Total |
|---|---|---|---|
| Mean | 63.9 ± 13.0 | 66.6 ± 13.8 | 65.3 ± 13.4 |
| Sex: Female, Male(Participants) | Vorinostat + Decitabine, Concurrent | Vorinostat + Decitabine, Sequential | Total |
|---|---|---|---|
| Female | 11 | 18 | 29 |
| Male | 23 | 19 | 42 |
No study locations are listed for this record.
The record gives a start of Jun 2007, a primary completion of Apr 2010 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2011, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vorinostat · Decitabine